BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1353 related articles for article (PubMed ID: 10400039)

  • 21. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
    Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
    Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
    Rouzier R; Extra JM; Klijanienko J; Falcou MC; Asselain B; Vincent-Salomon A; Vielh P; Bourstyn E
    J Clin Oncol; 2002 Mar; 20(5):1304-10. PubMed ID: 11870173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
    Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
    Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
    Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with operable breast cancer and positive axillary nodes at initial diagnosis.
    Rebollo-Aguirre AC; Gallego-Peinado M; Sánchez-Sánchez R; Pastor-Pons E; García-García J; Chamorro-Santos CE; Menjón-Beltrán S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(4):240-5. PubMed ID: 23684711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.
    Brady EW
    Breast J; 2002; 8(2):97-100. PubMed ID: 11896755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.
    Patel NA; Piper G; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Aug; 70(8):696-9; discussion 699-700. PubMed ID: 15328803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
    Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
    BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.